Mismatch repair defects as a cause of resistance to cytotoxic drugs

References

• Tindall KR, Glaab WE, Umar A etal. Complementation of mismatch repair genedefects by chromosome transfer. Mutat. Res. 402(1–2), 15–22 (1998).
   Google Scholar
• Jiricny J, Nystrom-Lahti M. Mismatch repair defects and cancer. Cum Opin. Genet. Dev. 10(2), 157–161 (2000).
   Google Scholar
• Obmolova G, Ban C, Hsieh P, Yang W Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA. Nature 407(6805), 703–710 (2000).
   PubMedGoogle Scholar
• Lamers MH, Perrakis A, Enzlin JH et al. The crystal structure of DNA mismatch repair protein MutS binding to a GxT mismatch. Nature 407(6805), 711–717 (2000).
   PubMedGoogle Scholar
• Lynch HT, Smyrk T. Hereditary nonpolyposis colorectal cancer (Lynchsyndrome). An updated review. Cancer 78(6), 1149–1167 (1996).
   PubMed Web of Science ®Google Scholar
• Pei-tom:Ai P DNA mismatch repair gene mutations in human cancer. Environmental I-kalth Penpectives105(S4), 775–780 (1997).
   Google Scholar
• Ricciardone MD, Ozcelik T, Cevher B et al. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis Type 1. Cancer Res. 59(2), 290–293. (1999).
   Google Scholar
• Wang Q, Lasset C, Desseigne F et al. Neurofibromatosis and early onset of cancers in hMLH1-deficient children. Cancer Res. 59(2), 294–297 (1999).
   Google Scholar
• Fishel R, Kolodner RD. Identification of mismatch repair genes and their role in the development of cancer. CUI7: Opin. Genet. Dev 5(3), 382–395 (1995).
   Google Scholar
• Gartenhaus RB. Microsatellite instability in hematologic malignancies. Leuk. Lymphoma 25(5-6), 455–461 (1997).
   PubMed Web of Science ®Google Scholar
• Schwartz S, Yamamoto H, Navarro M et al. Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res. 59(12), 2995–3002 (1999).
   Google Scholar
• Calm GA, Gara R, Tibiletti MG et al. Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: A study of the TG113Rff, BAX HMSH3, HMSH6, IGFIIRand BLMgenes. Int. j Cancer89(3), 230–235 (2000).
   Google Scholar
• Boyer JC, Umar A, Risinger JI et al. Microsatellite instability, mismatch repair deficiency and genetic defects in human cancer cell lines. Cancer Res. 55(24), 6063–6070 (1995).
   Google Scholar
• Kat A, Thilly WG, Fang WH et al. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc. Natl Acad. Sc]. USA 90(14), 6424–6428 (1993).
   Google Scholar
• Branch P, Aquilino G, Bignami M, Karran P Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362(15 April), 652–654 (1993).
   Google Scholar
• Risinger JI, Umar A, Barrett JC, Kunkel TA. A hPMS2 mutant cell line is defective in strand-specific mismatch repair. j Biol. Chem. 270(31), 18183–18186 (1995).
   Google Scholar
• Umar A, Koi M, Risinger JI et al. Correction of hypermutability, N-methyl-N'-nitro-N- nitrosoguanidine resistance and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res. 57(18), 3949–3955 (1997).
   Google Scholar
• Koi M, Umar A, Chauhan DP et al Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N- nitrosoguanidine tolerance in colon tumor cells with homozygous hWILH1 mutation. Cancer Res. 54(16), 4308–4312 (1994).
   Google Scholar
• Duckett DR, Drummond JT, Murchie AT et al. Human MutSalpha recognizes damaged DNA base pairs containing 06-methylguanine, 04-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl Acad. Sci. USA 93(13), 6443–6447 (1996).
   Google Scholar
• Dosch J, Christmann M, Kaina B. Mismatch G-T binding activity and MSH2 expression is quantitatively related to sensitivity of cells to methylating agents. Catrinogenesis 19 (4), 567–573 (1998) .
   Google Scholar
• Berardini M, Mazurek A, Fishel R. The effect of 06-methylguanine DNA adducts on the adenosine nucleotide switch functions of hMSH2-hMSH6 and hMSH2- hMSH3. j Biol. Chem. 275 (36), 27851–27857 (2000).
   Google Scholar
• •This study demonstrated that 06-methylguanine lesions, when paired with either a C or T, were bound by MutSa, but more importantly that this binding activated the ADP -> ATP exchange and ATPase activity of the heterodimer, known to be fundamental to repair activity.
   Google Scholar
• D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E et al. Involvement of the mismatch repair system in temozolomide- induced apoptosis. Mal Pharmacol 54(2), 334–341 (1998).
   PubMed Web of Science ®Google Scholar
• Duckett DR, Bronstein SM, Taya Y, Modrich P hMutSoc- and hMutLoc-dependent phosphorylation of p53 in response to DNA methylator damage. Proc. Natl Acad. Sci. USA 96(22), 12384–12388 (1999).
   Google Scholar
• Toft NJ, Winton DJ, Kelly J et al Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc. Natl Acad. Sci. USA 96(7), 3911–3915 (1999).
   Google Scholar
• Hickman MJ, Samson LD. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc. Natl Acad. Sci. USA 96(19), 10764–10769 (1999).
   Google Scholar
• Pegg AE. Repair of 0(6)-alkylguanine by alkyltransferases. Mutat. Res. 462(2–3), 83–100 (2000).
   Google Scholar
• Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyOnitrosourea. Cancer Res. 56(23), 5375–5379 (1996).
   Google Scholar
• Hawn MT, Umar A, Carethers JM et al. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res. 55(17), 3721–3725 (1995).
   Google Scholar
• Swann PF, Waters TR, Moulton DC et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 273(5278), 1109–1111 (1996).
   PubMed Web of Science ®Google Scholar
• Waters TR, Swann PE Cytotoxic mechanism of 6-thioguanine: hMutSoc, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochemistry 36 (9), 2501–2506 (1997).
   Google Scholar
• Drummond JT, Anthoney A, Brown R, Modrich P Cisplatin and adriamycin resistance are associated with MutL a and mismatch repair deficiency in an ovarian tumor cell line. J. Biol. Chem. 271(33), 19645–19648 (1996).
   Google Scholar
• Fink D, Nebel S, Aebi S et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56(21), 4881–4886 (1996).
   Google Scholar
• Fink D, Zheng H, Nebel S et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 57(10), 1841–1845 (1997).
   Google Scholar
• •This paper reports that treatment of a mixed population of MMR-proficient and -deficient cells with cisplatin and other chemotherapeutic agents led to enrichment of the deficient cells. This emergence of MMR-deficient cells was also shown in vivo in biopsies of ovarian tumors from patients undergoing cisplatin therapy.
   Google Scholar
• Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin AR, Brown R. Microsatellite instability, apoptosis and loss of p53 function in drug- resistant tumor cells. Cancer Res. 56(6), 1374–1381 (1996).
   Google Scholar
• Vaisman A, Varchenko M, Umar A et al. The role of hMLH1, hMSH3 and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res. 58(16), 3579–3585 (1998).
   Google Scholar
• Fink D, Nebel S, Norris PS et al. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int.j Cancer77 (5), 741–746 (1998).
   Google Scholar
• Yamada M, O'Regan E, Brown R, Karran P Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic Acids Res. 25(3), 491–495 (1997).
   Google Scholar
• Nehmé A, Baskaran R, Aebi S et al. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and deficient cells exposed to cisplatin. Cancer Res. 57(15), 3253–3257 (1997).
   Google Scholar
• Gong JG, Costanzo A, Yang HQ et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399 (6738), 806–809 (1999).
   Google Scholar
• Aebi S, Fink D, Gordon R et al. Resistance to cytotoxic drugs in DNA mismatchrepair-deficient cells. Clin. Cancer Res. 3(10), 1763–1767 (1997).
   PubMedGoogle Scholar
• las Alas MM, Aebi S, Fink D, Howell SB, Los G. Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J. Natl Cancer Inst. 89 (20), 1537–1541 (1997).
   Google Scholar
• Friedman HS, Johnson SP, Dong Q et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res. 57(14), 2933–2936 (1997).
   Google Scholar
• Cunningham JM, Christensen ER, Tester DJ et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 58(15), 3455–3460 (1998).
   Google Scholar
• Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 17(18), 2413–2417 (1998).
   Google Scholar
• Veigl ML, Kasturi L, Olechnowicz J et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Floc. Natl Acad. Sc]. USA 95(15), 8698–8702 (1998).
   Google Scholar
• Herman JG, Umar A, Polyak K et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl Acad. Sc]. USA 95(12), 6870–6875 (1998).
   Google Scholar
• Kane MF, Loda M, Gaida GM et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 57(5), 808–811 (1997).
   Google Scholar
• Bearzatto A, Szadkowski M, Macpherson P, Jiricny J, Kaman P Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents. Cancer Res. 60 (12), 3262–3270 (2000).
   Google Scholar
• Indraccolo S, Minuzzo S, Nicoletti L et al. Mutator phenotype in human hematopoietic neoplasms and its association with deletions disabling DNA repair genes and bc1-2 rearrangements. B/ooc/94(7), 2424–2432 (1999).
   Google Scholar
• Zhu YM, Das-Gupta EP, Russell NH. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. B/ooc/94(2), 733–740 (1999).
   Google Scholar
• Drummond JT, Genschel J, Wolf E, Modrich P DHF1?7I4SH3amplification in methotrexate-resistant cells alters the hMutSaihMutS13 ratio and reduces the efficiency of base-base mismatch repair. Floc. Natl Acad. Sc]. USA 94(19)10144-10149 (1997).
   Google Scholar
• Marra G, Iaccarino I, Lettieri T et al. Mismatch repair deficiency associated with overexpression of the MSH3gene. Proc. Natl. Acad. Sc]. USA 95(15), 8568–8573 (1998).
   Google Scholar
• Fink D, Nebel S, Norris PS et al. The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. BE J. Cancer 77(5), 703–708 (1998).
   Google Scholar
• Brown R, Hirst GL, Gallagher WM et al hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15(1), 45–52 (1997).
   Google Scholar
• Samimi G, Fink D, Varki NM et al. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin. Cancer Res. 6(4), 1415–1421 (2000).
   Google Scholar
• Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the h/V/LH/ promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18(14), 2335–2341 (1999).
   Google Scholar
• Geisler JP, Geisler HE, Miller GA et al. Immunohistochemical staining of the mismatch repair gene, hMSH2 and survival in patients with ovarian carcinoma. Eur Cynaecol Oiled 21(3), 237–240 (2000).
   Google Scholar
• Mackay HJ, Cameron D, Rahilly M et al. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. j Clin. Oncol 18(1), 87–93 (2000).
   Google Scholar
• •This paper describes a key clinical study that showed a correlation between loss of MLH1 expression in breast cancer tissue after primary, cisplatin-based chemotherapy and a poorer disease-free survival.
   Google Scholar
• Friedman HS, McLendon RE, Kerby T et al DNA mismatch repair and 06-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. j Clin. Oncol (1998) 16(12), 3851–3857.
   PubMedGoogle Scholar
• Wei Q, Eicher SA, Guan Y et al. Reduced expression of hMLH1 and hGTBP/ hMSH6: a risk factor for head and neck cancer. Cancer Epiclemiol Biomarkers Prey. 7(4), 309–314 (1998).
   Google Scholar
• Maehara Y, Oda S, Sugimachi K. The instability within: problems in current analyses of microsatellite instability. Mutat.Res. 461(4), 249–263 (2001).
   Google Scholar
• Edelmann W, Yang K, Umar A et al Mutation in the mismatch repair gene Nbh6 causes cancer susceptibility. Cell 91(4), 467–477 (1997).
   Google Scholar
• Brisco MJ, Sykes PJ, Dolman G et al. Early resistance to therapy during induction in childhood acute lymphoblastic leukemia. Cancer Res. 60(18), 5092–5096 (2000).
   Google Scholar
• Berry SE, Garces C, Hwang HS et al. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation and radiosensitization in human colon cancer cells. Cancer Res. 59(8), 1840–1845 (1999).
   Google Scholar
• Berry SE, Davis TVV, Schupp JE et al. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine. Cancer Res. 60(20), 5773–5780 (2000).
   Google Scholar
• Aquilina G, Ceccotti S, Martinelli S, Hampson R, Bignami M. N- (2-chloroethyl)- N'-cyclohexyl-N-nitrosourea sensitivity in mismatch repair-defective human cells. Cancer Res. 58(1), 135–141 (1998).
   Google Scholar
• Fiumicino S, Martinelli S, Colussi C et al. Sensitivity to DNA cross-linking chemotherapeutic agents in mismatch repair-defective cells in vitro and in xenografts Int.j Cancer 85 (4), 590–596 (2000).
   Google Scholar
• Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 60(21), 6039–6044 (2000).
   Google Scholar
• Tentori L, Vernole P, Lacal PM et al. Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic cells. Leukemia 14(8), 1451–1459 (2000).
   PubMedGoogle Scholar
• Tentori L, Turriziani M, Franco D et al. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia 13(6), 901–909 (1999).
   PubMedGoogle Scholar